Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-κB and Myc/Max

被引:118
|
作者
Kirch, HC [1 ]
Flaswinkel, S [1 ]
Rumpf, H [1 ]
Brockmann, D [1 ]
Esche, H [1 ]
机构
[1] Univ Essen Gesamthsch, Sch Med, Inst Mol Biol Canc Res, D-45122 Essen, Germany
关键词
p53; promoter; transcription; AP-1; NF-kappa B; Myc/Max;
D O I
10.1038/sj.onc.1202626
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Transcriptional control of p53 expression participates in the generation of appropriate le, els of active p53 in response to mitogenic stimulation, This prompted us to study the role of a putative AP-1 and a NF-kappa B motif in the human p53 promoter for transcriptional regulation, We show that mutation of the AP-1 or the NF-kappa B motif abolishes transcription from the human p53 promoter in HeLa, HepG2 and adenovirus type 5 E1-transformed 293 cells, In comparison, mutation of the previously characterized Myc/Max/USF binding site in the human p53 promoter reduces the transcription rate fivefold. The AP-1 motif in the human p53 promoter binds c-Fos and c-Jun and the NF-kappa-B motif binds p50(NF-kappa B1) and p65(RelA). The cooperative nature of transcriptional activation by these factors was documented by repression of c-fos or NF-kappa B1 translation: Pretreatment of the cells,vith a c-fos or p50(NF-kappa B1) antisense oligonucleotide suppresses transcription from the human p53 promoter completely. In addition, we show that (a) the level of endogenous p53 mRNA and (b) transcription from the strictly p53-dependent human mdm2 promoter are reduced in the presence of c-fos, c-jun, p50(NF-kappa B1), p65(RelA) or c-myc antisense oligonucleotides, underscoring the importance of these transcription factors for the expression of functional p53.
引用
收藏
页码:2728 / 2738
页数:11
相关论文
共 50 条
  • [41] Activated p53 induces NF-κB DNA binding but suppresses its transcriptional activation
    Kawauchi, Keiko
    Araki, Keigo
    Tobiume, Kei
    Tanaka, Nobuyuki
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 372 (01) : 137 - 141
  • [42] Dial 9-1-1 for p53: Mechanisms of p53 activation by cellular stress
    Ljungman, M
    NEOPLASIA, 2000, 2 (03): : 208 - 225
  • [43] Mutant p53 exerts its gain of function through activation of the NF-κB pathway
    Damalas, A
    Weis, L
    Nordgard, SH
    Kristensen, VN
    Gardner, K
    Cheng, G
    Gelinas, C
    Levrero, M
    Strano, S
    Borresen-Dale, AL
    Rotter, V
    Oren, M
    Blandino, G
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S53 - S53
  • [44] Mutant p53 exerts its gain of function through activation of the NF-κB pathway
    A Damalas
    L Weis
    SH Nordgard
    VN Kristensen
    K Gardner
    G Cheng
    C Gelinas
    M Levrero
    S Strano
    AL Børresen-Dale
    V Rotter
    M Oren
    G Blandino
    Breast Cancer Research, 7
  • [45] p53 Attenuates Lipopolysaccharide-Induced NF-κB Activation and Acute Lung Injury
    Liu, Gang
    Park, Young-Jun
    Tsuruta, Yuko
    Lorne, Emmanuel
    Abraham, Edward
    JOURNAL OF IMMUNOLOGY, 2009, 182 (08): : 5063 - 5071
  • [46] In vitro transcriptional activation of p21 promoter by p53
    Kim, TK
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 234 (02) : 300 - 302
  • [47] P73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints
    Wang, Shulin
    El-Deiry, Wafik S.
    CANCER RESEARCH, 2006, 66 (14) : 6982 - 6989
  • [48] Induction of TNF-sensitive cellular phenotype by c-myc involves p53 and impaired NF-κB activation
    Klefstrom, J
    Arighi, E
    Littlewood, T
    Jäättelä, M
    Saksela, E
    Evan, GI
    Alitalo, K
    EMBO JOURNAL, 1997, 16 (24): : 7382 - 7392
  • [49] Differential regulation of bcl-2, p53, AP-1 and NFκB on cardiomyocyte apoptosis during ischemic preconditioning
    Maulik, I
    Addya, S
    Galang, N
    Engelman, RM
    Das, DK
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 349A - 349A
  • [50] P53 GENETIC ABNORMALITIES AND MYC ACTIVATION IN HUMAN LUNG-CARCINOMA
    GAZZERI, S
    BRAMBILLA, E
    DEFROMENTEL, CC
    GOUYER, V
    MORO, D
    PERRON, P
    BERGER, F
    BRAMBILLA, C
    INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (01) : 24 - 32